EyeGate Pharmaceuticals, Inc.Find Ratings Reports
EYEGATE PHARMACEUTICALS INC's gross profit margin for the first quarter of its fiscal year 2021 has significantly increased when compared to the same period a year ago. While net income decreased, sales have remained unchanged. EYEGATE PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 4.74 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 36.13% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY21||Q1 FY20|
|Net Sales ($mil)||0.0||0.0|
|Net Income ($mil)||-2.58||-1.95|
|Balance Sheet||Q1 FY21||Q1 FY20|
|Cash & Equiv. ($mil)||6.61||5.88|
|Total Assets ($mil)||20.62||12.19|
|Total Debt ($mil)||0.52||0.15|
|Profitability||Q1 FY21||Q1 FY20|
|Gross Profit Margin||0.0||0.0|
|Return on Assets||-42.29||-81.39|
|Return on Equity||-68.75||-106.46|
|Debt||Q1 FY21||Q1 FY20|
|Share Data||Q1 FY21||Q1 FY20|
|Shares outstanding (mil)||7.1||4.63|
|Div / share||0.0||0.0|
|Book value / share||1.79||2.01|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||30145.0||54784.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 1.92 indicates a significant discount versus the S&P 500 average of 4.54 and a significant discount versus the subsector average of 10.83. The price-to-sales ratio is well above both the S&P 500 average and the subsector average, indicating a premium. The valuation analysis reveals that, EYEGATE PHARMACEUTICALS INC seems to be trading at a premium to investment alternatives.
|EYEG NM||Peers 28.65||EYEG NM||Peers 20.01|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
EYEG's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
EYEG's P/CF is negative making the measure meaningless.
|EYEG NM||Peers 16.37||EYEG NA||Peers 0.51|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
EYEG's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|EYEG 1.92||Peers 10.83||EYEG 43.57||Peers -60.49|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
EYEG is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
EYEG is expected to have an earnings growth rate that significantly exceeds its peers.
|EYEG 2441.71||Peers 28.96||EYEG NA||Peers 25.90|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
EYEG is trading at a significant premium to its subsector.
Neutral. Comparing a company's sales growth to its subsector helps to determine if the company is adding or losing market share.
The growth rate for EYEG is not available.